Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?
Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?
复制标题
DOI：
10.1186/1742-2094-10-144
复制
发表时间：
2013-12-01
影响因子：
9.3
通讯作者：
Maggirwar SB
中科院分区：
文献类型：
--
作者：
Davidson DC;Jackson JW;Maggirwar SB
人类免疫缺陷病毒1型（艾滋病毒）仍然是迄今为止最普遍的全球健康问题之一。抗逆转录病毒联合治疗（cART）的出现和引入对感染过程产生了重大影响。然而，随着患者寿命的延长，许多艾滋病毒相关疾病在感染人群中变得普遍，特别是那些与慢性炎症有关的疾病。一直以来，hiv相关的神经炎症被认为是hiv相关神经认知障碍（HAND）发展的主要催化剂，据估计，无论cART如何，大约50%的感染者仍会持续存在这种疾病。这极大地强调了开发有效的辅助疗法来控制疾病这方面的需要，而这是目前所缺乏的。我们之前证明，与未受损的感染者相比，认知受损感染者的血浆和脑脊液中炎症介质可溶性CD40配体（sCD40L）升高。我们的研究小组和其他人最近已经证明，这种炎症介质在hiv相关神经炎症的发病机制中发挥着越来越重要的作用，从而确定了这种分子作为治疗HAND的潜在治疗靶点。血小板是循环sCD40L的主要来源，这些小细胞越来越多地参与多种炎症性疾病，包括HIV感染期间常见的炎症性疾病。因此，减少血小板源性炎症介质（如sCD40L）释放的抗血小板疗法是治疗hiv相关神经炎症的一种创新的、非传统的方法，有可能使其他hiv相关疾病受益。
Human immunodeficiency virus type 1 (HIV) continues to be one of the most prevalent global health afflictions to date. The advent and introduction of combined antiretroviral therapy (cART) has made a significant impact on the course of infection. However, as patients are living longer, many HIV-associated illnesses are becoming prevalent among the infected population, especially those associated with chronic inflammation. Consistently, HIV-associated neuroinflammation is believed to be a major catalyst in the development of HIV-associated neurocognitive disorders (HAND), which are estimated to persist in approximately 50% of infected individuals regardless of cART. This dramatically underscores the need to develop effective adjunctive therapies capable of controlling this aspect of the disease, which are currently lacking. We previously demonstrated that the inflammatory mediator soluble CD40 ligand (sCD40L) is elevated in both the plasma and cerebrospinal fluid of cognitively impaired infected individuals compared to their non-impaired infected counterparts. Our group, and others have recently demonstrated that there is an increasing role for this inflammatory mediator in the pathogenesis of HIV-associated neuroinflammation, thereby identifying this molecule as a potential therapeutic target for the management of HAND. Platelets are the major source of circulating sCD40L, and these small cells are increasingly implicated in a multitude of inflammatory disorders, including those common during HIV infection. Thus, antiplatelet therapies that minimize the release of platelet-derived inflammatory mediators such as sCD40L are an innovative, non-traditional approach for the treatment of HIV-associated neuroinflammation, with the potential to benefit other HIV-associated illnesses.
登录
查看更多内容
影响因子：
3.7
作者：
Archin NM;Cheema M;Parker D;Wiegand A;Bosch RJ;Coffin JM;Eron J;Cohen M;Margolis DM
通讯作者：
Margolis DM
影响因子：
4
作者：
Combes, Valery;Coltel, Nicolas;Grau, Georges Emile
通讯作者：
Grau, Georges Emile
影响因子：
1.9
作者：
Dau B;Holodniy M
通讯作者：
Holodniy M
影响因子：
4.9
作者：
DiCenzo, R;Peterson, D;Schifitto, G
通讯作者：
Schifitto, G
影响因子：
8.8
作者：
Asaduzzaman, Muhammad;Lavasani, Shahram;Thorlacius, Henrik
通讯作者：
Thorlacius, Henrik